https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-07-01 / Expert Opin Biol Ther 2008 Jul;8(7):865-74
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-07-01 / Expert Opin Biol Ther 2008 Jul;8(7):865-742008-07-01 00:00:002019-02-15 08:44:34Maximizing dendritic cell migration in cancer immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-07-01 / Clin. Cancer Res. 2008 Jul;14(13):4298-305
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-07-01 / Clin. Cancer Res. 2008 Jul;14(13):4298-3052008-07-01 00:00:002019-02-15 08:53:22Dendritic cell vaccination with xenogenic polypeptide hormone induces tumor rejection in neuroendocrine cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-06-27 / BMC Immunol. 2008 Jun;9:32
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-06-27 / BMC Immunol. 2008 Jun;9:322008-06-27 00:00:002019-02-15 08:50:17Ex vivo recovery and activation of dysfunctional, anergic, monocyte-derived dendritic cells from patients with operable breast cancer: critical role of IFN-alpha
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-06-16 / Int. J. Urol. 2008 Aug;15(8):694-8
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-06-16 / Int. J. Urol. 2008 Aug;15(8):694-82008-06-16 00:00:002019-02-15 08:48:09Dendritic cell therapy in combination with interferon-alpha for the treatment of metastatic renal cell carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-05-15 / Clin. Cancer Res. 2008 May;14(10):3098-104
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-05-15 / Clin. Cancer Res. 2008 May;14(10):3098-1042008-05-15 00:00:002021-11-15 14:47:03Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-04-24 / Vaccine 2008 Jun;26(27-28):3540-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-04-24 / Vaccine 2008 Jun;26(27-28):3540-92008-04-24 00:00:002019-02-15 08:49:58Therapeutic vaccination with dendritic cells pulsed with tumor-derived Hsp70 and a COX-2 inhibitor induces protective immunity against B16 melanoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-04-09 / Trends Mol Med 2008 May;14(5):228-35
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-04-09 / Trends Mol Med 2008 May;14(5):228-352008-04-09 00:00:002019-02-15 08:46:53Cell- and peptide-based immunotherapeutic approaches for glioma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-03-01 / Bull Cancer 2008 Mar;95(3):320-6
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-03-01 / Bull Cancer 2008 Mar;95(3):320-62008-03-01 00:00:002019-02-15 08:51:24Immunotherapy of hematological malignancies using dendritic cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-02-08 / Crit. Rev. Oncol. Hematol. 2008 May;66(2):118-34
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-02-08 / Crit. Rev. Oncol. Hematol. 2008 May;66(2):118-342008-02-08 00:00:002019-02-15 08:49:32Dendritic cell vaccines in melanoma: from promise to proof?
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-02-01 / Expert Rev Anticancer Ther 2008 Feb;8(2):243-57
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-02-01 / Expert Rev Anticancer Ther 2008 Feb;8(2):243-572008-02-01 00:00:002019-02-15 08:52:23Immunotherapy opportunities in ovarian cancer
